Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2005-06-28
2005-06-28
Stucker, Jeffrey (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S323000, C530S324000, C530S325000, C530S326000, C530S327000, C530S826000, C435S005000, C435S007100, C424S188100, C424S199100, C424S208100
Reexamination Certificate
active
06911527
ABSTRACT:
This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
REFERENCES:
patent: 0471407 (1992-02-01), None
patent: 0673948 (1995-09-01), None
patent: 91/09872 (1991-07-01), None
patent: 94/02614 (1994-02-01), None
patent: 94/02626 (1994-02-01), None
patent: 99/66046 (1999-12-01), None
patent: 99/66957 (1999-12-01), None
patent: 99/66957 (1999-12-01), None
Riffkin et al. “A Single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”,Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp. 433-444.
Cruse et al.Illustrated Dictionary of Immunology(Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul,Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Feinberg et al. “AIDS vaccine models: Challenging challenge viruses” Nature Medicine, vol. 8, No. 3(Mar. 2002), pp. 207-210.
Nath et al. “The Chimpanzee and other non-human-primate models in HIV-1 vaccine research”, Trends in Microbiology, vol. 8, No. 9(2000), pp. 426-431.
Bonnycastle, et al.; “The Identification of “HIV-1-mimic” Peptides Using Antibodies from the Sera of HIV-1 Infected, Long-Term Non-Progressors;”Conf Adv AIDS Vaccine Dev; May 4-7, 1997; p. 109; United States.
Boots, et al.; “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries;”AIDS Research and Human Retroviruses; 1997; vol. 13; No. 18; Mary Ann Liebert, Inc.
Buchbinder, et al.; “HIV-Infected Long-Term Nonprogressors: Epidemiology, Mechanisms of Delayed Progression, and Clinical and Research Implications;”Microbes and Infection; Nov. 1999; pp. 1113-1120; vol. 1.
Cotropia, et al.; “A Human Monoclonal Antibody to HIV-1 gp41 With Neutralizing Activity Against Diverse Laboratory Isolates;”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; 1996; pp. 221-232; vol. 12; Lippincott-Raven Publishers; Philadelphia.
D'Souza et al.; “Evaluation and Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials;”The Journal of Infectious Diseases; 1997; pp. 1056-1062; vol. 175.
Felici, et al; “Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector;”Journal of Molecular Biology; 1991; pp. 301-310; No. 2; Academic Press Limited; London, Great Britain.
Haesevelde, et al.; “Genomic Cloning and Complete Sequence Analysis of a Highly Divergent African Human Immunodeficieny Virus Isolate;”Journal of Virology; Mar. 1994; pp. 1586-1596; vol. 68; No. 3; American Society for Microbiology.
Hogervorst, et al.; “Predictors for Non-and Slow Progression in Human Immodeficiency Virus (HIV) Type 1 Infection: Low Viral RNA Copy Numbers in Serum and Maintenance of High HIV-1 p24-Specific but Not V3-Specific Antibody Levels;”The Journal of Infectious Diseases; 1995; pp. 811-821; vol. 171; The University of Chicago.
Ida, et al; “HIV Type 1 V3 Variation Dynamics in Vivo: Long-Term Persistence of Non-Syncytium-Inducing Genotypes during the Course of Progressive AIDS;”AIDS Research and Human Retroviruses; 1997; pp. 1597-1609; vol. 13, No. 18; Mary Ann Liebert, Inc.
Montefiori, et al.; Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors;The Journal of Infectious Diseases; 1996; pp. 60-87; vol. 173; The University of Chicago.
Pantaleo et al.; “Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection;”Long-Term Nonprogressive HIV Infection; Jan. 26, 1995; pp. 209-216; vol. 332; No. 4; The New England Journal of Medicine.
Rusconi, et al.; “Patterns of in Vitro Anti-Human Immunodeficiency Virus Type 1 Antibody Production in Long-Term Nonprogressors;”Clinical Immunology and Immunopathology; Dec. 1997; pp. 320-323; vol. 85; No. 3; Academic Press.
Toran, et al. Molecular Analysis of HIV-1 gp120 Antibody Response using Isotype IgM and IgG phage display libraries from a Long-Term Non-Progressor HIV-1-Infected Individual;Eur. J. Immunol; 1999; pp. 2666-2675; vol. 29; Wiley-VCH Verlag GmbH; Weinheim.
Veronese, et al; “Structural Mimicry and Enhanced Immunogenicity of Peptide Epitopes Displayed on Filamentous Bacteriophage The V3 Loop of HIV-1 gp120;”J. Mol Biol.; 1994; pp. 167-172; vol. 243; Academic Press Limited.
Chen Xueni
Cohen Oren J.
Fauci Anthony S.
Scala Giuseppe
Stucker Jeffrey
The United States of America as represented by the Secretary of
Townsend and Townsend and Crew
LandOfFree
HIV related peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV related peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV related peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3478200